Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mark Boguniewicz
Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52‐Week, Phase 3 Trial (INTEGUMENT‐OLE) - Eichenfield - Pediatric Dermatology - Wiley O
1 Introduction Global prevalence of atopic dermatitis (AD) in those aged 6 months to < 18 years is 12%–15% [1]. Itch, sleep deprivation, impaired social functioning, and mental/physical comorbidities occurring with AD signs/symptoms [2] can negatively impact patient and family quality of life [2, 3].
Pioneering Progress in Pediatric Care: Managing Moderate to Severe Atopic Dermatitis
Medscape.org provides accredited, ad-free, and evidence-based independent education Medscape Education is a grant-funded group within the Medscape organization that maintains editorial independence to ensure unbiased educational material. View All (0) You haven't saved any activities just yet but once you do, they will show here so that you can easily access them whenever you're ready.Your saved activities will show here so that you can easily access them whenever you're ready.
Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities
Conflict of Interest Amy Paller has been an Investigator for AbbVie, Biomendics, Dermavant, Eli Lilly, Incyte, Johnson & Johnson Innovative Medicine, Regeneron, UCB; Consultant for Abeona, Arcutis, BioCryst, Boerhinger-Ingelheim, Castle Creek, Chiesi, Dermavant, Johnson & Johnson Innovative Medicine, Krystal, LEO Pharma, Lilly, L’Oreal, MoonLake Immunotherapeutics, Peltheos, Quoin, Regeneron, and Sanofi; Data safety monitoring board for AbbVie, Abeona, Biocryst, Daiichi Sankyo, and Galderma.
Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL‐13 inhibition
Pivotal phase 3 clinical trials of tralokinumab in adult AD The phase 3 clinical trials in adults, ECZTRA 1/2 (monotherapy),22 and ECZTRA 3 (combination with topical corticosteroids [TCS] as needed)21 are summarized in Figure 2 and Table 1. Overview of study design and inclusion criteria for pivotal phase 3 tralokinumab clinical trials: ECZTRA 1, 2, and 3.
Efficacy of Abrocitinib Rescue Therapy in the Phase 3 Study JADE REGIMEN
Main Article Content Jonathan I. Silverberg Mark Boguniewicz Kim Papp Athanasios Tsianakas Pinaki Biswas Claire Feeney Mark Levenberg Keywords Abrocitinib, JAK1 inhibitor, Moderate-to-Severe Atopic Dermatitis, JADE REGIMEN References 1. Boguniewicz M et al. Ann Allergy Asthma Immunol. 2018;120:10-22. 2. Blauvelt A et al. J Am Acad Dermatol. 2022;86:104-112. Article Sidebar Article Details How to Cite Silverberg, J. I. ., Boguniewicz, M., Papp, K., Tsianakas, A., Biswas, P., Feeney, C., & Levenberg, M.
Dupilumab Reduces Inflammatory Biomarkers in Patients Aged 6 Months to 18 Years With Moderate-to-Severe or Severe Atopic Dermatitis
Elevated levels of inflammatory biomarkers are observed in atopic dermatitis (AD). Dupilumab is associated with reduction of type 2 inflammatory biomarkers in adults, but data from adolescent and pediatric patients are lacking.
Dupilumab Efficacy in Children With Atopic Dermatitis Aged 6 Months to 5 Years With and Without Atopic Comorbidities
Atopic dermatitis (AD) is a chronic inflammatory systemic disease that frequently occurs with atopic comorbidities. Here, we evaluate the efficacy of dupilumab with concomitant topical corticosteroids (TCS) for moderate-to-severe AD in children with and without asthma, allergic rhinitis, and food allergies.
Dupilumab Treatment Reduces Total IgE Levels in Patients 6 Months and Older with Moderate-to-Severe Atopic Dermatitis
Efficacy of Lebrikizumab in Patients With Atopic Dermatitis and Atopic Comorbidities: Pooled Results From Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
Efficacy of Lebrikizumab in Patients With Atopic Dermatitis and Atopic Comorbidities: Pooled Results From Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
Atopic comorbidities are common in patients with atopic dermatitis (AD). We evaluated lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, in patients with AD with and without atopic comorbidities in 2 Phase 3, randomized, double-blind trials (ADvocate1 [NCT04146363] and ADvocate2 [NCT04178967]).
Effect of Abrocitinib and Dupilumab on Eosinophil Levels in Patients With Moderate-to-Severe Atopic Dermatitis and With or Without Comorbid Asthma or Allergic Rhinitis: A Post Hoc Pooled Analysis of JADE COMPARE and JADE DARE
Eosinophilia is common in patients with type 2 inflammatory diseases, including atopic dermatitis (AD), asthma, and allergic rhinitis. This post hoc analysis assessed the effects of abrocitinib and dupilumab on eosinophilia in patients with moderate-to-severe AD, with or without comorbid asthma or allergic rhinitis.
Validation of Remote AD Severity Assessment with the Eczema Area and Severity Index (EASI) Using Photos and Videos: Preliminary Reliability and Validity
Fecal microbiome changes in response to airway exposure to environmental peanut in household dust suggests a lung-gut axis
Efficacy of Abrocitinib Rescue Therapy in the Phase 3 Study JADE REGIMEN
JADE REGIMEN examined maintenance of abrocitinib-induced response with continual, reduced dose, or withdrawal of abrocitinib in patients with moderate-to-severe atopic dermatitis. Patients who lost response (flared) during the maintenance period received rescue treatment. This post hoc analysis evaluated the efficacy of rescue therapy.
The Infectious Complications of Atopic Dermatitis
Objective Atopic dermatitis (AD) is a chronic inflammatory skin disease that is complicated by an increased risk for skin and systemic infections. Preventive therapy for AD is based on skin barrier improvement and anti-inflammatory treatments, whereas overt skin and systemic infections require antibiotics or anti-viral treatments. This review updates the pathophysiology, diagnosis, management, controversy of antibiotic use, and potential treatments of AD infectious complications.
Patient burden and quality of life in atopic dermatitis in US adults
Abstract Background The patient burden and quality of life (QOL) impact of atopic dermatitis (AD) in the United States population is not well established. Objective To elucidate the patient burden of AD in the US population. Methods A cross-sectional, population-based study of 602 adults was performed. Atopic dermatitis was determined using modified UK Diagnostic Criteria for AD.
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape Mark BoguniewiczxMark BoguniewiczSearch for articles by this authorAffiliationsDivision of Allergy–Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, ColoradoCorrespondenceReprints: Mark Boguniewicz, MD, Division of Allergy–Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, 1400...
Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial
BACKGROUND AND OBJECTIVES: Atopic dermatitis (AD) primarily affects infants and young children. Although topical corticosteroids (TCSs) are often prescribed, noncorticosteroid treatments are needed because compliance with TCSs is poor due to concerns about their side effects.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mark
Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack